

# Index

Note: Page numbers of article titles are in **boldface** type.

- ADRENAL** glands, and Hodgkin's disease, 99  
**Albumin**, in Hodgkin's disease, 112  
**Alcohol-induced pain**, in Hodgkin's disease, 109–110  
**Alpha-chain disease**, 13  
**Amino acids**, and Hodgkin's disease, i11  
**Amyloidosis**, and Hodgkin's disease, 112  
**Antibodies**, in Hodgkin's disease, 119  
**Anticonvulsants**, and malignant lymphomas, 29–30  
**Antigens**, in Hodgkin's disease, 119  
**Appendectomy and Hodgkin's disease**, 15  
**Autoimmune disease**—  
and Hodgkin's disease, 120  
and malignant lymphoma, 27–29
- BLOOD** chemistries, 84  
**Bone marrow**, and Hodgkin's disease, 102–103  
Bone marrow biopsy, in non-Hodgkin's lymphoma, 137–141  
Bone marrow evaluation, 80  
Bones, and Hodgkin's disease, 103–104  
Burkitt's lymphoma, chemotherapy and, 207  
Burkitt's tumour, 59–60
- CALCIUM**, and Hodgkin's disease, 110  
**Cells**—  
red blood, and Hodgkin's disease, 113–115  
white blood, and Hodgkin's disease, 115  
**Cellular immunity**, failure of, in Hodgkin's disease, 117–119  
**Central nervous system**—  
and Hodgkin's disease, 104–107  
involvement in non-Hodgkin's lymphoma, 151–152  
**Chemotherapy**—  
as primary treatment for Hodgkin's disease, 197  
Burkitt's lymphoma and, 207  
choice in Hodgkin's disease, 197–202  
choice of patients with non-Hodgkin's lymphoma for, 208
- Chemotherapy**—(*continued*)  
combination, 198–200  
in non-Hodgkin's lymphomas, 154, 202–208  
single-agent, 197–198  
treatment of patients in whom quadruple is ineffective, 201  
**Childhood lymphosarcoma**, chemotherapy and, 207  
**Clinicopathologic correlations**, 64–68  
**Cytogenetics of lymphomas**, 9–10
- DERMATOMYOSITIS**, and Hodgkin's disease, 109  
**Drug administration and toxicity in Hodgkin's disease**, 200–201
- ENZYMES**, and Hodgkin's disease, 113  
**Epitrochlear lymphadenopathy**, in non-Hodgkin's lymphomas, 151  
**Epstein-Barr virus and malignant lymphomas**, 17–19  
**Erythrocyte sedimentation rate in Hodgkin's disease**, 117  
**Extralymphatic disease**, localised, and initial stage of involvement in non-Hodgkin's lymphomas, 143–144
- FEVER**, and Hodgkin's disease, 108–109
- GASTROINTESTINAL tract**—  
and Hodgkin's disease, 96  
involvement in non-Hodgkin's lymphoma, 148–151  
**Genitourinary tract**, and Hodgkin's disease, 104  
**Globulins**, in Hodgkin's disease, 112
- HAEMATOPOIETIC diseases**, 39  
**Heart as site of Hodgkin's disease**, 95  
**Hepatic Hodgkin's disease**, 101–102

- Histiocytic lymphomas, 57-59  
 Histopathology of malignant lymphomas, 39-69  
 Hodgkin's disease, 61-63  
     and other lymphomas, staging of, 77-88  
     and skin lesions, 107  
     cellular basis of, 5-7  
     chemotherapy for, 195-202  
     classification of, 77-80  
     clinical features and course of, 91-120  
     clinical stages I and II, radiotherapy and, 165-172  
     clinical stages III and IV, radiotherapy and, 180-183  
     clinicopathic studies, 64-66  
     complications, 108-117  
     complications due to metabolic and endocrine abnormalities, 110-113  
     delayed hypersensitivity in, 117-118  
     drug-induced effects of, 106-107  
     epidemiology of, 11-12  
     familial, 20-21  
     haemotogenous spread of, 100-107  
     haematologic complications, 113-117  
     histocompatibility antigens and, 21-22  
     immune responsiveness in, 24-25  
     immunologic complications, 117-120  
     immunological factors and radiotherapy, 177  
     mediastinal involvement, and radiotherapy, 177-179  
     neurological complications of, 104-105  
     non-specific clinical manifestations of, 108-110  
     of the lungs, 93-95  
     origin and progression, 92  
     pathology of, 4-7  
     radiotherapy in, 161-183  
     radiotherapy and correlation of occult disease and clinical data, 174-176  
     radiotherapy and liver involvement, 174  
     radiotherapy and the extent of intra-abdominal lesions, 173-174  
     retroperitoneal and intra-abdominal, 95-99  
     sites of, 92-108  
     surgery, 86-88  
     techniques of radiotherapy in, 162-165  
     tentative classification, 179-180  
     tissue-associated antigens, 19-20  
     tonsillectomy, appendectomy and the development of, 15  
     transmissibility of, 14-15  
     treatment of patients in whom quadruple chemotherapy is ineffective, 201  
     use of drugs in, 196-197  
 Homograft rejection in Hodgkin's disease, 118  
 Hormones, and Hodgkin's disease, 113  
 Hydroxyproline, and Hodgkin's disease, 111-112  
 Hypertrophic osteoarthropathy and Hodgkin's disease, 110  
 IMMUNE responsiveness in Hodgkin's disease, 24-25  
 Immune-complex nephritis, 29  
 Immunodeficiency states and lymphomas, 25-27  
 Immunologic deficiencies and diseases, and Hodgkin's disease, 119-120  
 Infections, and Hodgkin's disease, 105-106, 118-119  
 KAPOSI'S sarcoma, 13-14  
 LAPAROTOMY, in non-Hodgkin's lymphomas, 142-143  
 Leucocyte HL-A phenotypes in Hodgkin's disease, 115-116  
 Liver, and Hodgkin's disease, 101-102  
 Liver biopsy in non-Hodgkin's lymphomas, 141-142  
 Lymphocytes in Hodgkin's disease, 116-117  
 Lymphocytic-histiocytic lymphomas, mixed, 56-57  
 Lymphocytic lymphomas—  
     poorly differentiated, 55  
     well-differentiated, 54-55  
 Lymphoma—  
     and alpha-chain disease, 13  
     anatomical site, and histological type of, 9  
     non-Hodgkin's, radiotherapy and, 183-190  
     primary intestinal, 12-13  
     undifferentiated non-Burkitt's, 61  
 Lymphoma induction, chronic graft-v-host reaction and, 22-24  
 Lymphomas—  
     aetiological leads in the malignant, 3-31  
     and Kaposi's sarcoma, 13-14  
     anticonvulsants, and malignant, 29-30  
     autoimmune disease and malignant, 27-29  
     chemotherapy of the, 195-208  
     classification of malignant, 44, 46, 49-51  
     clinical features and course of non-Hodgkin's, 131-158  
     clinicopathic studies of non-Hodgkin's, 66-68  
     cytogenetics, 9-10  
     diffuse, 157-158  
     diffuse malignant, 53-61  
     epidemiology, 10-14

**Lymphomas—(continued)**

Epstein-Barr virus and malignant, 17-19  
histopathology of malignant, 39-69,  
51-64  
historical observations and concepts of  
malignant, 42-49  
immunodeficiency states and, 25-27  
immunologic aspects of malignant, 19-29  
impaired immune function and the  
development of, 22  
inherent and acquired susceptibility to  
the development of, 20  
nodular, 158  
nodular (follicular), 51-53  
non-Hodgkin's, 7-8 (*see also* non-  
Hodgkin's lymphomas)  
non-Hodgkin's, epidemiology of, 12  
pathology of malignant, 4-8  
radiotherapy in the treatment of malig-  
nant, 161-190  
role of external factors in, 10-19  
surgery and, 86-88  
viral aetiology and, 15-19  
Lymphoreticular neoplasms, 39-42  
Lymphosarcoma, childhood, chemotherapy  
and, 207

MALIGNANT lymphomas, pathology of, 4-8  
Mediastinum site of Hodgkin's disease, 93  
Metabolic effects of Hodgkin's disease, 106  
Metals and Hodgkin's disease, 110-111  
Mycosis fungoides, 61

NEPHRITIS, immune-complex, 29  
Nephrotic syndrome, and Hodgkin's  
disease, 120  
Nodular (follicular) lymphoma, 51-53  
Non-Hodgkin's lymphoma—  
age and sex at diagnosis of, 145  
choice of patients with, for chemotherapy,  
208  
clinical and laboratory investigations of  
Stages I and II, 184-185  
clinical features and course of, 131-158  
clinical staging, 137-145  
constitutional symptoms, 146  
correlation between survival and histo-  
logic type, 135-137  
diffuse or disseminated forms (Stages III  
and IV), 188-190  
evolution and prognosis, 187-188  
histopathology of, 131-137

**Non-Hodgkin's lymphoma—(continued)**

immunological features, 152-153  
intrathoracic manifestation of, 146-147  
local and regional forms (Stages I and II),  
184-188  
mode of spread, 144-145  
natural history and interpretation of  
treatment results, 153-157  
radiotherapy and, 183-190  
results of radiotherapy, 185-187

PERICARDIUM site of Hodgkin's disease, 95  
Phosphorus, and Hodgkin's disease, 110  
Pruritus, and Hodgkin's disease, 109, 111  
Pyrimidines, and Hodgkin's disease, 111

RADIATION therapy in non-Hodgkin's lym-  
phomas, 154-157  
Radiographic evaluation, 81-84  
Radiotherapy—  
chemotherapy as adjuvant treatment to,  
196-197  
in the treatment of malignant lymphoma,  
161-190  
Reticuloendothelial malignancies, 39-42

SCANNING and nuclear medicine, 84-86  
Skin lesions and Hodgkin's disease, 107  
Skin testing, 84  
Spinal cord, and spread of Hodgkin's  
disease, 97  
Spleen, as site of Hodgkin's disease, 99-100  
Splenectomy, in non-Hodgkin's lympho-  
mas, 142-143  
Staging of Hodgkin's disease and other  
lymphomas, 77-88  
Subdiaphragmatic disease, 188

THYMUS, as site of Hodgkin's disease, 95  
Tonsillectomy and Hodgkin's disease, 15

URIC acid, and Hodgkin's disease, 111

VIRAL aetiology of lymphomas, 15-19

WALDEYER's ring, involvement of in non-  
Hodgkin's lymphomas, 147-148



# Index

Note: Page numbers of article titles are in **boldface** type.

This index does not contain an exhaustive list of the haemoglobin variants mentioned in the text. A full list of haemoglobin mutants appears in Tables 2-6, pp. 256-265.

- ACID-elution technique for fetal haemoglobin, 545  
Africans,  $\alpha$  thalassaemia among, 278  
Alkali-denaturation procedures for fetal haemoglobins, 546-547  
Allosteric effectors, 365  
 $\alpha$  chain, 216, 250-251  
  excess in  $\beta$  thalassaemia, 414-416  
  of Hb F, genetic control of, 472  
  variants, 270-271, 498  
 $\alpha$ -globin-gene duplication, 447-448  
 $\alpha$  thalassaemia, *see* thalassaemia,  $\alpha$   
Amino acid—  
  deletions, 262-264, 335-336  
  replacement at haem-contact, 335  
  replacement by proline, 339  
  substitutions, 262  
 $S_2\gamma$ aminoethyl derivative of  $\alpha$  or non- $\alpha$  chain, formation of, 562  
Anaemia—  
  aplastic, haemoglobin F in, 492-493  
  in sickle cell, 288-322  
  in  $\alpha$  thalassaemia, 387, 391  
  in  $\beta$  thalassaemia, 419, 427  
  refractory, with hyperplastic bone marrow, haemoglobin F in, 493-494  
Anion-exchange chromatography, 538-540  
Antenatal diagnosis of haemoglobinopathies, 522-523  
Aplastic crises in sickle-cell anaemia, 312  
Autohaemolysis test in unstable haemoglobin disorders, 347
- $\beta$  CHAIN—216, 250-251  
  deficiency, in  $\beta$  thalassaemia, 412-414  
  variants, 269-270, 557-558  
 $\beta$  thalassaemia, *see* thalassaemia,  $\beta$   
Blood, collection, transportation, and preparation of for haemoglobin analysis, 529  
Blood transfusion, in  $\alpha$  thalassaemia, 406  
  in  $\beta$  thalassaemia, 429-431  
Bohr effect, and abnormalities of haemoglobin, 368-370
- Bohr protons, 362-363  
Bone infarcts, sterile, in sickle-cell anaemia, 313
- CATION-exchange chromatography, 536-538  
Cell membrane, in  $\beta$  thalassaemia, 417  
Cellulose-acetate electrophoresis, 532-533  
  and isoelectrofocussing, 543
- Chains—  
  *see* individual chains, i.e.  $\alpha$ -,  $\beta$ -,  $\delta$ -,  $\gamma$ -, etc.  
Chains, globin—  
  elongation in protein synthesis, 232  
  identification after PMB treatment, 561  
  initiation in protein synthesis, 230-232  
separation—  
  by column chromatography, 561  
  by counter current distribution, 561  
termination in protein synthesis, 233-234  
termination mutants, 264  
Cholelithiasis, 407  
Chromatographic methods—  
  Amberlite IRC 50, 538  
  CM-cellulose, 536  
  DEAE-sephadex, 542-543  
  DE-52-cellulose, 542  
  evaluation of methods, 540-541  
  in determination of fetal haemoglobin, 547  
  in diagnosis of haemoglobinopathies, 536-541  
  separation of chains by, 561
- Chromosomal anomalies, fetal haemoglobin levels with, 488
- Chromosomal location, linkage between genes and, 254-255
- Chromosomal proteins, 438-440
- Chromosomal organisation, 438-441
- Contacts, subunit, substitution of amino acids in, 339
- Cord-blood samples, detection of abnormal haemoglobins in, 556-558
- Crossing-over, mechanism of, 446-447
- Cyanate, and sickling, 320

- DACTYLITIS** in sickle-cell disease, 312
- δ-chain variants**, 271
- δ thalassaemia**, 275
- δβ thalassaemia**, 274–275
- Diagnosis of the haemoglobinopathies**, 527–564  
  antenatal, **509–564**
- DNA** in chromosomes, 438
- 2,3-diphosphoglycerate**—  
  binding, abnormalities involving the sites of, 370  
  determination of, 558–559  
  effect on haemoglobin function, 221, 365, 468  
  metabolism, abnormalities of, 374
- ELECTROPHORESIS**, haemoglobin, 346–347, 585–586  
  evaluation of methods, 535–536  
  in diagnosis of haemoglobinopathies, 530–536
- 'Erythron', in β thalassaemia, 417–422
- Erythropoiesis**, transcriptional unit and, 444
- Erythropoietin** metabolism, abnormalities of, 374–375
- Eukaryotic cells**, regulatory genes in, 443–444
- FERRARA**, β thalassaemia in, 457
- Fetal erythropoiesis** and the developmental sequence of the embryonic and fetal haemoglobins, 470–472
- Fetal haemoglobin**, *see* Haemoglobin F
- Folic-acid deficiency** in sickle-cell disease, 313
- Frame-shift mutants**, 264–266
- F thalassaemia**, 274–275
- Fusion chain variants**, 266–269, 499, *see also* Haemoglobin Lepore; Haemoglobin Kenya
- γ CHAIN**—  
  control of, 472–475  
  variants, 271, 498, 556, 557
- γ thalassaemia**, 276
- γβ thalassaemia**, 500
- Gene**—  
  deletion and thalassaemia, 450–451  
  frequency, 441–442  
  mutations affecting two non-allelic, 271  
  recombination, 445–451  
    significance of, 447  
  regulatory, in eukaryotic cells, 443–444  
  regulatory, the operon, and thalassaemia, 445  
  structural haemoglobin genes and their regulation, 252–254
- Genetic control**—  
  of adult haemoglobins, **251–280**
- Genetic Control**—(continued)  
  of fetal haemoglobins, 472–475  
  of haemoglobin in thalassaemia, 276–277
- Globin**—  
  structure of, 219–220  
  synthesis, 229–235, 387
- Glycogen**, red-cell, in β thalassaemia, 417
- Greek form** of hereditary persistence of fetal haemoglobin, 482–486
- HAEM contact amino acids**, replacement of, 335
- Haem-haem interaction**, 363, 365
- Haem-pocket**—  
  abnormalities of, 367–368  
  structure of, 218–219
- Haem-protein ratio**, determination of, 553–554
- Haem synthesis**, 228–229
- Haematuria**, 316
- Haemichromes**, role of in denaturation of unstable haemoglobins, 351
- Haemodynamics and oxygen transport**, 299–300
- Haemoglobin**—  
  abnormal, 262–269, 367–374  
  electrophoresis, 346–347  
  genetic control of, 251–280  
  normal human, 216, 251–255  
  with abnormal oxygen transport, 357–382  
  structure and function of, **217–222**, 356–367  
  synthesis, **225–243**  
    hereditary abnormalities of, 272–279  
    regulation of, 235–243  
    switch from fetal to adult, 477–481  
  unstable, **333–353**  
    bone marrow in, 342–345  
    clinical features and laboratory findings, 339–348  
    complications and treatment, 349–350  
    differential diagnosis, 348  
    genetic features, 339–341  
    Hb-A<sub>2</sub> and Hb-F levels, 347  
    heat denaturation test in, 345
- Haemoglobin A<sub>2</sub>**, 216  
  determination of, 542–544  
  variants, of 271
- in β thalassaemia, 413
- Haemoglobin Bart's**, 499–500, *see also* thalassaemia, α  
  hydrops fetalis, 387–390  
  in newborn period, 386
- haemoglobin A + Bart's disease, 395
- haemoglobins A + E + Bart's disease, 398
- haemoglobins E + F + Bart's disease, 398
- Haemoglobin C** Harlem trait, 318

- Haemoglobin Constant Spring, 215, 216  
geographical distribution, 401–402  
molecular mechanism of, 266  
 $\alpha$  thalassaemia and, 384, 402
- Haemoglobin F, **567–502**  
abnormalities of the structure and synthesis of, 498–500  
chromosomal anomalies, 488  
clinical significance of, 293  
determination of, 544–549  
evaluation of methods, 548–549  
genetic control of, 472–475  
haemoglobin S/hereditary persistence of, 311–312  
hereditary persistence of, 280, 482  
Negro, Greek and Swiss types, 482–486  
persistent, in adults, 481–488  
relationship between structure and function of, 476–477  
synthesis, 501–502  
in  $\beta$  thalassaemia, 413
- Haemoglobin H, 390  
inclusion bodies in  $\alpha$  thalassaemia, 387  
disease, 340–345  
geographical distribution, 400
- Haemoglobin Kenya, 499
- Haemoglobin Lepore, 448–450
- Haemoglobin-Lepore thalassaemia, 275
- Haemoglobin Olympia, 374
- Haemoglobin S, 288 ff  
hereditary persistence of fetal haemoglobin and, 311–312
- Haemoglobin S/ $\beta$  thalassaemia, 308–309
- Haemoglobin S/C disease, 309–310
- Haemoglobin S/D Punjab disease, 310–311
- Haemoglobin S/O Arab disease, 311
- Heat denaturation test, 345
- Heat stability test, 551–552
- Heinz bodies, 342  
formation, mechanism of, 350–351
- Hybridisation of globin chains, 560
- IMMUNOLOGICAL characterisation in identifying haemoglobin abnormalities, 563–564
- Immunological method in diagnosis of  $\alpha$  thalassaemia, 387
- Inclusion bodies, stains for, 527–528
- Infection, susceptibility to, in sickle-cell anaemia, 304–305
- Iron, in  $\beta$  thalassaemia, 416
- Iron chelation, 407  
in  $\beta$  thalassaemia, 431–432
- Isoelectric focussing, 534–535
- Isopropanol precipitation test, 552–553
- Isotope studies, 348
- LEUKAEMIA, haemoglobin F in, 491
- Leukaemia—(*continued*)  
juvenile chronic myeloid, 490–491
- Linkage—  
between haemoglobin genes, 254–255  
of the  $\beta$ -globin gene and the  $\beta$ -thalassaemia mutation, 450
- MALARIA, and sickle-cell disorders, 305
- Messenger RNA, 234–235  
and the thalassaemia defect, 455–457  
translational control and, 457–458
- Methaemoglobinaemia, 346
- Mutations, terminator, 460, *see also* Haemoglobin Constant Spring
- Myoglobin, 358–360
- NECROSIS, aseptic, in sickle-cell anaemia, 313
- Negro form of hereditary persistence of fetal haemoglobinaemia, 482–486
- Negro  $\alpha$  thalassaemia/haemoglobin I, 396
- Negroes, haemoglobin S/ $\beta$  thalassaemia in, 309
- Non-polar residues, replacement of by polar residues, 335
- Nuclear RNA metabolism, 451–453
- Nucleoprotein, in  $\beta$  thalassaemia, 421–422
- OPERON, 443  
regulating genes, and thalassaemia, 445
- Osmotic-fragility tests, 347
- Osteomelitis in sickle-cell disease, 313
- Oxy-deoxy equilibrium within subunits, abnormalities affecting the, 370–371
- Oxy-haemoglobin S, mechanical instability of, 551
- Oxygen loading, mechanics of, 361–362
- Oxygen saturation, 559
- Oxygen transport, haemodynamics and, 299–300
- PCMB precipitation test, 553
- Penicillin, prophylactic after splenectomy in thalassaemia, 407
- Peptide analysis, 562–563
- pH determinations, 558
- PO<sub>2</sub> determinations, 559
- Polar residues, replacement of non-polar by, 335
- Priapism in sickle-cell disease, 315–316
- Proline, replacement of, 339
- Protein synthesis, 453–454
- Proteins, chromosomal, 438–440
- Pulmonary complications in sickle-cell anaemia, 315
- QUATERNARY structures, abnormalities affecting the equilibrium between, 371–374

- RED-cell life span, haemodialysis and, 301  
 Red-cell metabolism, 347  
 Red-cell production, 224–228  
 Renal function, disordered, in sickling disorders, 305–306  
 Rheology, abnormal in sickling disorders, 295–298  
 RNA processing, 452–453
- SALT bonds, abnormalities involving, 368–370  
**Sickle-cell anaemia, 288–322, 486–487**  
 aplastic crisis, 312  
 aseptic necrosis, 313  
 clinical features, 299–305  
 complications, 312–317  
 dactylitis, 312  
 fetal haemoglobin in, 293  
 haematuria, 316  
 incidence, 306  
 liver disease, 316  
 osteomyelitis, 313  
 painful crisis, 313  
 pathophysiology of, 289–290  
 priapism, 315–316  
 retinopathy, 316–317  
 rheology of blood in, 295  
 spleen in, 301–303  
 treatment, 318
- Sickle-cell trait, 317–318**  
**Sickle-cell  $\beta$  thalassaemia, 308–309**  
**Sickle-cell haemoglobin C disease, 309–310**  
**Sickle-cell haemoglobin D disease, 310–311**
- Sickling tests—  
 evaluation of methods, 550–551  
 Splenectomy, in  $\alpha$  thalassaemia, 406–407, 431  
 in  $\beta$  thalassaemia, 431  
 in unstable haemoglobin disorders, 349
- Splenic dysfunction in sickle-cell disorders, 301–303
- Starch-block electrophoresis, 543  
 Starch-gel electrophoresis, 530–532  
 Sulphaemoglobinaemia, 346
- THALASSAEMIA—**  
 definition of, 272–279  
 molecular defect in, **437–461**  
 $\alpha$  thalassaemia, 276–279, **383–408**  
 African, 278  
 and Hb Constant Spring, 278  
 classification of, 383–384  
 clinical features, 384–399  
 diagnosis, 386–387  
 genetics of, 402–405  
 geographical distribution of, 400–402  
 haemoglobin H disease, 390–395  
 in association with—  
      $\alpha$ -chain haemoglobin variants, 395
- $\alpha$  thalassaemia—(continued)  
 $\beta$ -chain haemoglobin variants, 396  
 $\beta$  thalassaemia and hereditary persistence of fetal haemoglobin, 279, 399  
 $\beta$  or  $\delta\beta$  thalassaemia, 399  
 haemoglobin C, 399  
 haemoglobin E, 396–398  
 haemoglobin S, 398–399  
 laboratory findings, 385–386  
 major (see also Haemoglobin Bart's hydrops), 387–390  
 management, 405–407  
 socio-economic problems, 407–408  
 traits, 384–385  
 $\alpha$  thalassaemia 1/haemoglobin-Constant Spring disease, 395  
 $\alpha$  thalassaemia 1/haemoglobin-Q disease, 396  
 $\alpha$  thalassaemia 2/Hb-Constant Spring/Hb-E trait, 398  
 $\alpha$ -thalassaemia trait/haemoglobin-E trait, 396–397  
 $\alpha$ -thalassaemia trait/homozygous Hb E, 398  
 $\beta$  thalassaemia, 272–274, **411–433**  
 $\alpha$ -chain excess in, 414  
 asymptomatic, 429  
 $\beta$ -chain deficiency in, 412  
 classification of, 413  
 clinical aspects and forms of, 425–429  
 compensatory mechanisms in, 424  
 effects of on whole organism, 423–424  
 in Ferrara, 457  
 haematological findings, 422  
 intermediate, clinical aspects, 427–429  
 management, 429–432  
     iron chelation, 431  
     splenectomy, 431  
 metabolic effects, 423  
 pathophysiology of, 412–426
- $\delta$  thalassaemia, 275  
 $\delta\beta$  thalassaemia, 274–275  
 combination of with  $\beta$  thalassaemia, 275
- $\gamma$  thalassaemia, 276  
 $\gamma\beta$  thalassaemia, 500
- F thalassaemia, 274–275  
 see also  $\delta\beta$ -thalassaemia
- Transcription, 451–452  
 Transcriptional regulation, 236–240  
 Transcriptional unit, 440–445  
     and erythropoiesis, 444
- Transfusion—  
 in haemoglobin H disease, 406  
 in sickling disorders, 318  
 in  $\beta$  thalassaemia, 429–431
- Translational control, 241–242  
 of mRNAs, 457–458
- UREA, and sickling disorders, 318–319





# Index

Note: Page numbers of articles are in **boldface** type.

## ANAEMIA

- and cardiovascular response to, 617-618
- and oxygen extraction by the tissues, 618-  
619
- and physical work capacity, **609-624**
- and respiratory response to exercise, 616-  
617
- estimates of the effect of on physical  
activity, 619-622
- functional considerations in, 613-616
- haematological normalcy and, 609-619
- iron deficiency, clinical symptoms, haemo-  
globin concentration and erythrocyte  
biochemistry, **689-702** (*see also* Iron  
deficiency anaemia)
- Anaemic hypoxia, 602-604

## BLOOD oxygen affinity, 2,3-DPG—

- in vitro, 630-632
- in vivo, 632-633

## CARDIORESPIRATORY disease, red cell adap- tation in, **627-644**

- Cardiovascular disease, and haemoglobin  
levels, 711-713
- Cardiovascular response to exercise, anaemia  
and, 617-618
- Cyanotic heart disease, 634-638

## 2,3-DIPHOSPHOGLYCERATE(2,3-DPG)—

- and in vitro blood oxygen affinity, 630-  
632
- inappropriate concentration of in abnor-  
mal haemoglobin function, 591
- 2,3-diphosphoglycerate interaction, haemo-  
globin function and, 579-580

## ERYTHROPOIETIN production during expo- sure to high altitudes, 601-602

- Exercise—
  - anaemia and cardiovascular response to,  
617-618
  - anaemic and respiratory response to, 616-  
617

## HAEMATOLOGICAL normalcy—

- and anaemia, 609-619
- functional considerations, 613-616
- Haemoglobin, adaptation to physical work  
with low levels of, 622-624
- Haemoglobin function, and 2,3-DPG inter-  
action, 579-580

## Haemoglobin function, abnormal, 585-592

- altered haemoglobin-ligand interaction  
in, 589-591
- altered oxygen affinity, 585-587
- altered shape of oxygen dissociation  
curve, 587-589
- inappropriate concentrations of 2,3-DPG,  
591

## therapeutic considerations, 591-592

## Haemoglobin levels, circulating—

- and mortality, 713-716
- approach to evaluating, 705-709
- clinical evaluation of, **705-717**
- symptoms in low, 709

## Heart disease—

- cyanotic, 634-638
- noncyanotic, 630-633

## Hypoxia—

- anaemic, 602-604
- red cell oxygen affinity and erythropoiet-  
in production, **595-605**
- the red cell in adaptation to anaemic,  
**577-592**

## INFECTION, and haemoglobin levels, 710

- Iron deficiency anaemia, study in women  
with, **689-702**

- biochemical findings, 695-698
- haematological findings and specificity of  
the diagnosis of, 693-695
- materials and methods used in, 693-701
- results, 693-701
- symptoms correlated with haematological  
and erythrocyte biochemical variables  
in, 698-701

## LUNG disease in adults and older children, 638-639

## MYOCARDIAL insufficiency in dogs, effect of preserved red cells with increased affinity for oxygen, 663

## NEONATAL respiratory distress syndrome, 639-640

## Noncyanotic heart disease, 630-633

## OXYGEN affinity—

- and regulation of oxygen binding capa-  
city, 599-601
- consequences of changes in, 640-643

- Oxygen affinity of human red cells—  
and oxygen transport to the tissues, 597–  
598  
regulation of, 595–597
- Oxygen binding capacity—  
and oxygen transport, 598–599  
oxygen affinity and regulation of, 599–601
- Oxygen transport, oxygen binding capacity  
and, 598–599
- Oxygen transport function of preserved  
red cells, 649–682, 664–668
- PHYSICAL** activity, estimates of the effect of  
anaemia on, 619–622
- Physical work, adaptation to with low levels  
of haemoglobin, 622–624
- Populations, haematological characteristics  
of, and therapeutic and supplementa-  
tion studies, 609–612
- RED** cell—  
adaptation in cardiorespiratory disease,  
627–644  
in adaptation to anaemic hypoxia, 577–  
592
- Red cell affinity for oxygen—  
in vitro measurements of, 652–653  
in vivo measurements of, 651–652
- Red cell 2,3-DPG, regulation of, 580–582
- Red cell function, normal, 578–584
- Red cell mass, reduction in, 582–584
- Red cells—  
oxygen transport function of preserved,  
**649–682**, 664–668  
physiological effect of human, with in-  
creased affinity for oxygen, 653–663  
regulation of the oxygen affinity of human,  
595–597  
with above normal 2,3-DPG levels and  
decreased affinity for oxygen, therapeu-  
tic effectiveness of, 669–681  
with increased affinity for oxygen, effect  
on myocardial insufficiency in dogs  
and on work performance in rats, 663
- Respiratory distress syndrome, neonatal,  
639–640
- Respiratory response to exercise, anaemia  
and, 616–617
- TRANSFUSION, exchange, in newborn infant,  
663
- WORK capacity—  
anaemia and physical, 609–624  
and haemoglobin levels, 710  
Work performance in rats, effect of pre-  
served red cells with increased affinity  
for oxygen, 663

